Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).
Journal Information
Full Title: J Infect Dis
Abbreviation: J Infect Dis
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Communicable Diseases
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Potential conflicts of interest. C. H., L. R., J. L., J. K. P., D. H., and D. P. P. are employees and shareholders of Gilead Sciences, Inc. A. L. G. reports contract testing from Abbott, Cepheid, Novavax, Pfizer, Janssen, and Hologic and research support from Gilead outside of the described work. M. G. is a consultant for Merck, Biogen, and HDT Bio. G. C. is a shareholder and former employee of Gilead Sciences, Inc and a current employee of Vir Biotechnology. All other authors report no potential conflicts. Potential conflicts of interest ."
"Financial support. This work was funded by Gilead Sciences, Inc and supported by the Infectious Diseases Clinical Research Consortium through the National Institute for Allergy and Infectious Diseases of the National Institutes of Health (grant number UM1AI148684). Funding to pay the Open Access publication charges for this article was provided by Gilead Sciences, Inc. Financial support ."
"Clinical Trials Registration. NCT04280705."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025